---
title: "Halozyme partners with Incyte on ENHANZE subcutaneous formulation for INCA033989 antibody"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293211642.md"
description: "Halozyme Therapeutics has entered a global collaboration and license agreement with Incyte to develop subcutaneous formulations of the INCA033989 antibody using Halozyme's ENHANZE technology. The partnership targets mutant calreticulin-expressing myeloproliferative neoplasms, aiming for more convenient dosing compared to current development plans. Financial terms include upfront payments, milestone payments, royalties on net sales, and an option for Incyte to add up to two additional targets."
datetime: "2026-07-20T12:05:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293211642.md)
  - [en](https://longbridge.com/en/news/293211642.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293211642.md)
generator: "portal-rs"
---

# Halozyme partners with Incyte on ENHANZE subcutaneous formulation for INCA033989 antibody

-   Halozyme entered a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using ENHANZE technology. \* Work targets mutant calreticulin-expressing myeloproliferative neoplasms, aiming for more convenient dosing and delivery versus current development plans. \* Terms include an upfront payment, milestone payments, royalties on net sales, and an option for Incyte to add up to two more targets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607200800PR\_NEWS\_USPR\_\_\_\_\_LA07615) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)

## Related News & Research

- [Vise Technologies Inc. Takes $743,000 Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296763264.md)
- [Wealthfront Advisers LLC Buys Shares of 9,753 Incyte Corporation $INCY](https://longbridge.com/en/news/296678417.md)
- [Halozyme CEO Helen Torley sells USD 4.13 million in common shares](https://longbridge.com/en/news/296412342.md)
- [Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296450253.md)
- [Active Biotech wins European regulatory approval to resume tasquinimod myelofibrosis trial enrollment](https://longbridge.com/en/news/296500289.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**